Wir verwenden standardmäßig essenzielle Cookies (Anmeldung, deine gespeicherten Ziele/Stacks). Mit deiner Erlaubnis aktivieren wir außerdem datenschutzfreundliche Analytik (Vercel Web Analytics, anonyme Ladezeit-Metriken) und Fehler-Replay-Diagnostik (Sentry — DOM-Snapshots nur, wenn ein Fehler auftritt), damit wir Bugs schneller beheben können. Mehr über Cookies erfahren
Can4.0
Canakinumab – Forschung
Überwiegend Mechanismus / Beobachtung
34 begutachtete Studien
Was die Evidenz sagt
Überwiegend Mechanismus / Beobachtung
Die meisten Studien zu Canakinumab sind mechanistisch oder beobachtend statt RCTs, die einen klinischen Effekt messen — betrachte die Ergebnisse als vorläufig.
Die meiste Evidenz stammt aus hochwertigen Meta-Analysen und randomisierten Studien, veröffentlicht 2009–2026 mit einer typischen Studiengröße von 80 Teilnehmenden.
Basierend auf 34 Studien · 5 Meta-Analysen · 11 RCTs · 17,092 Teilnehmende insgesamt
Konfidenz
Hohe Konfidenz
Nach Outcome
Inflammation & inflammagingSenkte dosisabhängig hsCRP und IL-6 ohne Auswirkung auf die Blutfettwerte — ein klarer Test der Entzündungshypothese · Wochen
Überwiegend Mechanismus / Beobachtung12 Studien
Cardiovascular (CANTOS)CANTOS zeigte, dass die 150-mg-Dosis wiederkehrende kardiovaskuläre Ereignisse bei Patienten nach Herzinfarkt reduzierte, unabhängig von jeglicher Veränderung der Blutfettwerte · Monate bis Jahre
Überwiegend Mechanismus / Beobachtung7 Studien
Cancer & periodic fever syndromes
Überwiegend Mechanismus / Beobachtung6 Studien
Safety profile
Überwiegend Mechanismus / Beobachtung6 Studien
Aging & healthspan (hypothesis)
Zu wenige bewertete Studien2 Studien
Aktives Forschungsgebiet
30 Studien in den letzten 5 Jahren · Neueste Meta-Analyse: 2025
200920172026
1Systematische Übersicht2026
We report a case of Schnitzler syndrome in a 49-year-old man refractory to anakinra and subsequently treated successfully with canakinumab.
De Santos Belinchón S, Ausín García C, Lorenzo Barcia PD, Pire García T, Balastegui Martín H, Muñoz Delgado C, Villalba García MV, Lavilla Olleros C. · Internal medicine journal (2026)
Schnitzler syndrome is a rare autoinflammatory syndrome caused by a dysregulation of the interleukin-1β signalling pathway.
Symptoms tend to appear in middle age and include urticariform skin lesions, fever, bone pain, lymphadenopathy and IgM monoclonal gammopathy.
Interleukin-1 (IL-1) targeted therapy constitutes the basis for treatment and can lead to complete resolution of symptoms.
Our study is the first to indicate the efficacy of CAN in reducing serum creatinine levels.
Koç E, Pekdiker M, Kara M. · Turkish journal of medical sciences (2026)
Of the total, 60% of the patients had an M694V homozygous mutation, and 41.5% were resistant to Anakinra.
The mean CAN treatment duration was 31.3 ± 23.1 months, and 80% of patients achieved complete remission, while 20% achieved partial remission.
Erythrocyte sedimentation rate, C-reactive protein, frequency of attacks, and patient global assessment decreased significantly after CAN (p < 0.001 for each).
We conclude by outlining a translational research agenda integrating inflammation-aware risk stratification, niche-directed imaging, and spatial multi-omics to guide precision anti-inflammatory interventions in MPN.
Abdelgawwad El-Sehrawy AAM et al. · Clinical and experimental medicine (2026)
Current cytoreductive strategies inadequately address this underlying biology, leaving substantial residual vascular risk.
We conclude by outlining a translational research agenda integrating inflammation-aware risk stratification, niche-directed imaging, and spatial multi-omics to guide precision anti-inflammatory interventions in MPN.
Their integration into clinical practice could enhance limb preservation and long-term cardiovascular outcomes.
Tudurachi A et al. · Biomolecules (2026)
Among newer indices, the neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, systemic immune-inflammation index, C-reactive protein-to-albumin ratio, and HALP (Hemoglobin, Albumin, Lymphocyte, and Platelet) score appear especially promising for risk stratification.
Anti-inflammatory and pleiotropic therapies, including canakinumab, colchicine, statins, and PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitors, may help reduce residual inflammatory risk.
Conclusions: Inflammatory biomarkers may improve prognostic stratification and support more personalized management in PAD.
These findings establish inflammation as a modifiable therapeutic target in the secondary prevention of CHD and support colchicine as the most advisable anti-inflammatory treatment currently available for CHD.
Hofmann U · Innere Medizin (Heidelberg, Germany) (2026)
These findings establish inflammation as a modifiable therapeutic target in the secondary prevention of CHD and support colchicine as the most advisable anti-inflammatory treatment currently available for CHD.
Published in Innere Medizin (Heidelberg, Germany) (2026)
REGISTRATION: This review was registered on PROSPERO (CRD420251118080).
Abhari AP, Rezvanian P, Sohrabi E, Hosseini K, Attauabi M, Gupta R, Najafi K. · BMC gastroenterology (2026)
HSCT (4 studies) achieved survival rates of 64%-100% and remission rates up to 92%, with pooled individual-level data indicating 82% survival and 69% remission.
Common complications included graft-versus-host disease (46%) and infections (64%).
CONCLUSIONS: HSCT is effective for monogenic VEO-IBD, especially IL10R deficiency, with substantial survival and remission rates despite notable risks, while biologics yield inconsistent results.
In this review, we highlight the historical discovery of IL-1, its involvement in various pathologies, and its role as a therapeutic target, with focus on its role in disorders pertinent to the clinical allergist/immunologist.
Broderick L et al. · Allergology international : official journal of the Japanese Society of Allergology (2026)
Since that time, the number of disorders implicating a role for IL-1 has expanded to more complex inborn errors of immunity, as well as more common polygenic disorders diagnosed and treated by the practicing allergologist, including asthma, allergic rhinitis and neutrophilic and atopic dermatoses.
In this review, we highlight the historical discovery of IL-1, its involvement in various pathologies, and its role as a therapeutic target, with focus on its role in disorders pertinent to the clinical allergist/immunologist.
By integrating cytokine biology, endothelial dysfunction, clinical trial outcomes, and emerging genomic stratifiers, it highlights opportunities and challenges in implementing biomarker- and genotype-guided strategies, treat-to-target approaches, and real-world considerations for cost-effectiveness and safety in secondary cardiovascular prevention.
Srivastava A, Dinesh D, Bhatia J, Arya DS. · Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie (2026)
This review synthesizes mechanistic, preclinical, and clinical evidence on immune-endothelial crosstalk in cardiovascular inflammation, with a focused appraisal of canakinumab as a precision anti-inflammatory therapy.
Published in Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie (2026)
Therefore, further research is required to minimize the gaps and to explore immunotherapy-based drugs as potential treatments for T1DM.
Salame G, Hakim V, Dagher C, Daou RM, Dada AE, Nassif L, Ghadieh HE, Azar S, Bazzi S, Harb F. · PloS one (2025)
Mean difference (MD) and standard mean difference (SMD) were used to evaluate the outcomes with a 95% confidence interval (CI).
The combined data showed that patients receiving immunotherapy had higher C-peptide levels (Mean Difference (MD) = 1.51; 95% Confidence Interval (CI): [-2.56, 5.58]); however, this difference was not statistically significant (p = 0.42).
On the other hand, patients in the immunotherapy group had significantly decreased HbA1c levels (MD = -0.63; 95% CI: [-1.18, -0.07]; p = 0.03), indicating that immunotherapy had a positive impact on glycemic management.
10Systematische Übersichtn=18 · very small study2025
We propose this as a consideration for future consensus discussions, emphasizing the potential benefits of early recognition and timely interleukin-1 inhibitor therapy to improve patient outcomes.
Zhu C, Martinez-Jaramillo E, Ben-Shoshan M, Netchiporouk E, Chergui M, Fein M. · Clinical and experimental dermatology (2025)
The majority of our population were male patients (56%) with a median age at diagnosis of 57.5 years (interquartile range 44.8-62.8).
Most of the patients had absent monoclonal gammopathy (n = 14; 78%), and four (22%) had delayed-onset monoclonal gammopathy.
Of the 14 patients treated with anakinra, 93% (n = 13/14) achieved a complete response.
There remains a significant unmet need for better outcome measures than just complete healing as well as better treatment options to improve patient outcomes.
Kaur M, Diaz MJ, Anthony M, Jolley D, Schildmeyer AH, McFeeters J, Kaffenberger BH. · International wound journal (2025)
The proportion of complete wound healing varies significantly across treatments and recurrence is common even in a limited follow-up period.
Heterogeneity of study methods and low numbers hamper disease research.
There remains a significant unmet need for better outcome measures than just complete healing as well as better treatment options to improve patient outcomes.
Considering the rarity, the potential severity and refractoriness to current treatments of the disease, there is a critical need for better understanding of pathophysiology and expert driven treatment guidelines for of BS-uveitis.
Maccora I, Wouters C, Rosè CD, Maniscalco V, de Masi S, Mastrolia MV, Marrani E, Pagnini I, Simonini G. · Journal of autoimmunity (2025)
The proportion of children showing improvement of uveitis was 20 % (95 % CI 2-46) and 22 % (95 % CI3-47) for cDMARDs and bDMARDs respectively (χ 2 0.23, p = 0.631).
No differences were observed among the administered drugs (χ 2 7.21, p = 0.706).
Conclusion The data show that there is not enough evidence to establish a preferred treatment for managing uveitis in BS.
Further studies are needed to evaluate the efficacy and complication profile of canakinumab against other biologic therapy options.
Yang HJ, Spratt W, Lai FYX, Lee S. · The Journal of dermatological treatment (2025)
Results A 44-year-old female achieved complete ulcer resolution after 31 months of canakinumab but experienced recurrent infections, including pneumonia requiring intensive care unit (ICU) admission.
A 49-year-old male showed no improvement and suffered recurrent Pseudomonas infections, leading to treatment cessation after nine months.
Conclusions We present a case series of two patients with PG on canakinumab therapy, both of whom experienced significant infections needing hospitalization.
Clinicaltrials gov registry (NCT05401578) and the Swiss National Clinical Trials Portal (SNCTP) on www.kofam.ch (SNCTP000004838).
Hepprich M, Fischer J, Cattaneo M, Ferreira A, Herzig D, Bally L, Donath M. · BMJ open (2025)
A significant improvement in any one of these outcomes will be considered sufficient to demonstrate the clinical superiority of canakinumab over placebo.
Results will be published in a relevant scientific journal and communicated to participants and relevant institutions through dissemination activities.
In this case-based review, we clarify the epidemiology of MEFV variants in collagen diseases and discuss the significance of their genetic analysis.
Ono N, Yoshimura M, Nishida T, Yamauchi Y, Doi G, Fuyuno Y, Sonoda M, Niiro H. · Modern rheumatology case reports (2025)
We experienced a recurrent MAS case with homozygous MEFV P369S variants accompanied by Sjögren syndrome and pulmonary arterial hypertension, whose recurrent MAS was successfully treated with canakinumab.
Pathogenicity of MEFV P369S variant is still inconsistent, and clinical interpretation of this variant is challenging.
Thus, we reviewed previous literatures and revealed that the majority of FMF patients with collagen diseases in carried MEFV P369S variant, all of which were reported from Japan.
Conclusions Among patients with JIA, canakinumab exhibited the highest likelihood of being the optimal treatment for achieving the modified ACRpedi30 response rate, and neither of the tested biological agents carried a significant risk of serious adverse events.
Wang B, Zhang Y, Zhao Z, Ping J, Zhou L, Wang Y, Zhang Y. · Medicine (2024)
Canakinumab (odds ratio 55.0, 95% credible intervals 2.4-67.0) was more effective than the placebo, and the difference was statistically significant.
The SUCRA shows that canakinumab ranked first (SUCRA, 86.9%), anakinra ranked second (SUCRA, 77.7%), adalimumab ranked third (SUCRA, 61.9%), and placebo ranked the last (SUCRA, 6.3%).
Nevertheless, there were no notable discrepancies in the occurrence of adverse events, hepatic-related adverse events, infectious adverse event, serious adverse events, and serious infection following treatment with canakinumab, anakinra, tocilizumab, rilonacept, or the placebo.
Woo J, Zhai T, Yang F, Xu H, Healey ML, Yates DP, Beste MT, Steensma DP. · Cancer prevention research (Philadelphia, Pa.) (2024)
These findings support a potential role for canakinumab in cancer prevention and provide evidence of IL1β blockade cooperating with CH mutations to modify the disease course.
Prevention Relevance: We reveal that administering canakinumab is associated with a decrease in non-hematological malignancies among patients with clonal hematopoiesis (CH) mutations.
Conclusion The addition of canakinumab to first-line pembrolizumab and CT did not prolong PFS or OS in patients with NSCLC.
Tan DSW, Felip E, de Castro G, Solomon BJ, Greystoke A, Cho BC, Cobo M, Kim TM, Ganguly S, Carcereny E, Paz-Ares L, Bennouna J, Garassino MC, Schenker M, Kim SW, Brase JC, Bury-Maynard D, Passos VQ, Deudon S, Dharan B, Song Y, Caparica R, Johnson BE. · Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)
With a median study follow-up of 6.5 months, the median PFS was 6.8 months with canakinumab versus 6.8 months with placebo (hazard ratio [HR], 0.85; 95% CI, 0.67 to 1.09; P = .102).
With a median study follow-up of 21.2 months, the median OS was 20.8 months with canakinumab versus 20.2 months with placebo (HR, 0.87; 95% CI, 0.70 to 1.10; P = .123).
A higher frequency of neutropenia and ALT increase (grade ≤2) were reported in the treatment arm.